Pay in 4 interest-free payments of $6.96 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
High dose oral cobalamin may be a suitable alternative in selective cases, where intramuscular injections are not tolerated and compliance is not a problem
GLP-1 Medications Show Promise for Improving HS Symptoms February 23, 2026 Authors: Allison Hanka, College of Biological Sciences, University of Minnesota, Minneapolis, MN Jordyn Nepper, BS, Department of Dermatology, University of Minnesota, Minneapolis, MN Noah Goldfarb, MD, Associate Professor, Departments of Medicine and Dermatology, University of Minnesota, Minneapolis, MN Why was this research done
D., Kramer, J
Furthermore, AI and machine learning methodologies can be incorporated for real-world data analysis such as for surveying social media trends for better understanding of patient experiences and misconceptions about GLP-1 RAs, in identification of potential treatment barriers like insurance coverage limitations and concerns regarding side effects for developing targeted interventions and also in evaluation of treatment efficacy in real-world settings
No, GLP-1 receptor agonists are not licensed by the MHRA specifically for treating inflammatory conditions
